Tag Archives | CRAMS

More changes at Jubilant?

Jubilant Organosys appears to be taking one more step in transforming itself into a pharmaceutical company. The company is looking at selling its industrial and performance products division and expects to realise Rs3.0-3.5bn from the sale, says this report in today’s Economic Times. There was no official confirmation on this from the company. The division, […]

Continue Reading

Not so fine anymore?

News is slowly trickling in of Indian pharmaceutical and fine chemical companies shutting down facilities that were acquired with great zeal during the 2005-08 overseas acquisition drive. Shasun has decided to shut its facility at Newbie in Scotland and is reportedly shifting manufacturing to other locations in the US, the UK and India. The Newbie […]

Continue Reading

Confident CRAMS

There are a few optimistic companies that are betting on growth in the midst of inflation, rising crude oil prices and a worldwide economic slowdown. Some custom research and manufacturing services (CRAMS) players believe that the pressure on costs will result in more outsourcing opportunities. This view is spurring investments with Dishman Pharmaceuticals and Chemicals […]

Continue Reading

Hikal scores in CRAMS

Hikal is busy consolidating its position in the Indian CRAMs (contract research and manufacturing services) space. It recently secured a long-term contract with Bayer CropScience for supply of active ingredients for crop protection chemicals. And now Hikal plans to invest Rs 2bn (US$50m) in setting up four new manufacturing facilities in Bangalore and Mumbai and […]

Continue Reading
world%20crams.JPG

Testing times for CRAMS

Business is booming in India’s custom research and manufacturing services (CRAMS) industry thanks to the country’s strong process chemistry skills, low operational costs and the availability of a skilled workforce. Frost & Sullivan values the Indian CRAMS market at $890m, and expects it to expand by 40% in 2008. It estimates the market for outsourcing […]

Continue Reading

CRAMs comes with challenges

India’s success in the global custom research and manufacturing services space (CRAMS) is well documented. And the untapped potential is huge especially as western pharmaceutical companies remain under pressure to cut costs. According to one estimate, the global manufacturing outsourcing opportunity is likely to grow from US$20bn in 2006 to US$31bn in 2010. The global […]

Continue Reading

CRAMS: still going strong

Indian companies in the contract research and manufacturing services (CRAMS) domain appear to be doing well as is reflected in the stock market performance of these companies. The list includes Divi’s Laboratories, Dishman Pharmaceuticals & Chemicals, Nicholas Piramal, Shasun Chemicals & Drugs, and Jubilant Organosys This report in today’s Economic Times highlights that CRAMS companies’ […]

Continue Reading

Opportunties in CRAMS

With an estimated annual growth of 25%, the Indian contract research and manufacturing services (CRAMS) sector is attracting global attention. Globally, drugs worth $70 billion would be going off-patent by 2011 and Indian companies providing contract manufacturing services are expected to grab approximately 30-40% of this opportunity. It is still early if Indian companies can […]

Continue Reading

Jubilant CRAMS another acquisition

Jubilant Organosys $123m acquisition of US-based Hollister-Stier Labs further consolidates is position in the global custom research and manufacturing (CRAMs) business. Interestingly, Jubilant will not be moving projects to India following the acquisition. In an interview with CNBC, Hari Bhartia, Jubilant’s managing director, says the company will be looking at expanding the Hollister-Stier facility and […]

Continue Reading

Indian chemicals score on CRAMS

Jubiliant Organosys’ announcement that it has clinched deals worth $60m from global life science majors reinforces India’s growing strength in the custom research and manufacturing services (CRAMS) business. Rising competition and research costs are supporting the CRAMS outsourcing wave and beneficiaries include Shasun Chemicals, Nicholas Piramal, Divis Lab and Dishman Pharma. A report in the […]

Continue Reading